KCM Investment Advisors LLC Increases Stock Position in AbbVie Inc. $ABBV

KCM Investment Advisors LLC increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 1.0% during the 2nd quarter, Holdings Channel reports. The firm owned 76,427 shares of the company’s stock after purchasing an additional 746 shares during the quarter. KCM Investment Advisors LLC’s holdings in AbbVie were worth $14,186,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Nuveen LLC purchased a new position in shares of AbbVie in the 1st quarter worth approximately $1,819,154,000. Assenagon Asset Management S.A. lifted its holdings in AbbVie by 550.9% during the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock worth $804,116,000 after acquiring an additional 3,666,521 shares during the period. Goldman Sachs Group Inc. lifted its holdings in AbbVie by 31.6% during the first quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company’s stock worth $3,068,820,000 after acquiring an additional 3,519,187 shares during the period. Kingstone Capital Partners Texas LLC purchased a new position in AbbVie in the second quarter worth $581,817,000. Finally, Invesco Ltd. grew its stake in AbbVie by 17.5% in the 1st quarter. Invesco Ltd. now owns 8,367,049 shares of the company’s stock valued at $1,753,064,000 after purchasing an additional 1,246,863 shares during the period. 70.23% of the stock is owned by institutional investors.

AbbVie Price Performance

NYSE ABBV opened at $218.92 on Friday. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The company has a market cap of $386.74 billion, a PE ratio of 104.25, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 52 week low of $163.81 and a 52 week high of $244.81. The firm’s 50-day simple moving average is $223.24 and its two-hundred day simple moving average is $202.30.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter last year, the company earned $3.00 earnings per share. The company’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 524.24%.

Insider Activity

In other AbbVie news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.25% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Citigroup decreased their target price on AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research report on Monday. Evercore ISI increased their price target on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research report on Monday, September 22nd. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a report on Monday. Hsbc Global Res cut shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Finally, Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and increased their target price for the company from $170.00 to $270.00 in a research report on Wednesday, September 17th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $236.57.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.